Incyte buys global rights for tafasitamab from MorphoSys

admin

Incyte buys global rights for tafasitamab from MorphoSys


Maksim Labkouski

Incyte (NASDAQ:INCY) has bought the global commercialization rights to the drug tafasitamab, also known as Monjuvi, from partner MorphoSys (NASDAQ:MOR) for $25M.

Incyte announced the deal soon after Novartis (NYSE:NVS) said that it had agreed to buy MorphoSys

SOURCE

Leave a Comment